{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-110119","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2023-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.919208+00:00","generated_at":"2026-06-09T21:07:53.189696+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AEON Biopharma Phase 2 migraine trial misses primary endpoint; secondary endpoints statistically significant","bullets":["Primary endpoint not met: mean MMD reduction of 4.8 days (150U) and 5.0 days (195U) vs 4.2 days placebo; p-values not significant (0.2844, 0.1711).","Secondary endpoint: 69% of 195U dose achieved ≥50% MMD reduction vs 52% placebo (p=0.0132); 75% reduction significant for both doses.","Safety profile favorable; Company plans to advance to Phase 3 and request end-of-phase 2 FDA meeting in H1 2024.","Ongoing Phase 2 for chronic migraine to complete enrollment in Q4 2023; topline data expected in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-110119","json":"https://secwatch.observer/filing/0001104659-23-110119.json","markdown":"https://secwatch.observer/filing/0001104659-23-110119.md","text":"https://secwatch.observer/filing/0001104659-23-110119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923110119/0001104659-23-110119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000110465923110119/tm2328542d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T21:07:53.189696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}